Business Wire

Inotrem’s COVID-19 Phase IIa Clinical Trial Declared “National Priority Research” by the French Government’s Clinical Trial Council

Share

Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government steering committee for therapeutic clinical trials and other research (CAPNET).

In the context of a substantial amount of COVID-19-related research and the launch of numerous clinical trials, the French government created this steering committee to prioritize and accelerate high potential clinical trials. The “National Priority Research” designation, granted by CAPNET on the basis of assessment conducted by the REACTing Scientific Council, facilitates accelerated enrollment of patients in clinical trials, the activation of fast-track reviews and approval processes conducted by the French regulatory authorities (ANSM) and the French Ethics Committee (CPP), and better valuing of research centers’ active contribution.

Inotrem’s Phase IIa clinical trial, which takes place in France, Belgium and the United States will determine the safety, tolerability and potential signals of efficacy of nangibotide, the company’s lead product, in critically ill COVID-19 patients. This Phase IIa trial follows a preliminary study conducted by Prof. Sébastien Gibot at the CHRU of Nancy, which showed that the TREM-1 pathway was activated in critically ill COVID-19 patients and associated with outcome. TREM-1 is an immunomodulatory receptor expressed on innate immune and endothelial cells which amplifies and maintains inflammation. Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021.

Jean-Jacques Garaud, CEO of Inotrem, indicates: “This Research National Priority designation is an endorsement of both the work we have accomplished so far in fighting the COVID-19 pandemic and of the high potential of our lead product, nangibotide, for treating patients in ICU suffering from severe forms of COVID-19. Thanks to the strong commitment of regulatory bodies and the funding provided by Bpifrance, France’s public investment bank, we were able with our partners, CHRU of Nancy and CHU of Limoges, to launch this study in a timely manner. This governmental designation will allow us to accelerate this study and more rapidly assess the therapeutic potential for patients suffering from severe forms of COVID-19.”

Prof. Sébastien Gibot, lead study investigator, adds: “We are very pleased with this decision which will allow us to accelerate patients’ enrollment in France; we plan on enrolling a total of 60 patients. Results of the study are expected early Q2 2021 and will determine the safety, tolerability and potential signals of efficacy of nangibotide in COVID-19 patients. Previous clinical studies have demonstrated nangibotide’s safety and tolerability in patients suffering from septic shock, which is also characterized by acute inflammatory syndromes.”

In parallel, Inotrem is currently conducting a Phase IIb trial (ASTONISH) to treat septic shock patients with nangibotide in six European countries and in the United States. Previous clinical studies with nangibotide in septic shock demonstrated that it was safe, well tolerated and showed signals towards clinically relevant efficacy. Pre-clinical models have shown that nangibotide modulates the amplification of the immune response caused by the activation of TREM-1 and is able to restore appropriate inflammatory response and vascular function, resulting in improved survival in septic shock models.

About Inotrem

Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com

About TREM-1 pathway

TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.

About Nangibotide

Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals’ survival post septic shock.

Contact information

Media contact for Inotrem
Anne REIN
Strategies & Image (S&I)
anne.rein@strategiesimage.com
+33 6 03 35 92 05

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yokogawa Selects C3 AI Suite to Enhance Enterprise AI Applications12.4.2021 09:00:00 CEST | Press release

C3 AI (NYSE: AI) and Yokogawa Electric Corporation (TOKYO: 6841) (“Yokogawa”) today announced that Yokogawa has selected the C3 AI® Suite as a platform to enhance enterprise AI applications and complement its digital transformation solutions and services for industrial customers. Yokogawa signed a multi-year agreement enabling the company and its wholly owned subsidiary, KBC, to deploy the C3 AI Suite with its advanced AI capabilities to their software portfolio. Yokogawa and KBC implement leading technology and best practices, turning strategy to results through technical and commercial excellence, underpinned by engineering simulation and analytics, and systematized through operational technology and digital services. Yokogawa expects C3 AI to play a critical role in its AI-enabled offerings that deliver optimized productivity for clients, greater levels of industrial autonomy, and creation of new business opportunities across vertical industries, including power generation, renewabl

Titomic & Néos to Manufacture Invar36 Faceplates in the UK12.4.2021 09:00:00 CEST | Press release

Titomic has signed a Heads of Agreement with Neos International Limited to form a joint venture in the United Kingdom which will manufacture and sell Invar 36 Faceplates and multi-metal product solutions for the Aerospace, Defence, Automotive and Nuclear industries. The products will be manufactured using Titomic’s Kinetic Fusion (TKF) Technology and Neos’ specialist engineering and tooling expertise. The Neos Titomic joint venture will enhance the rapid delivery of Invar and Nickel Shell Tooling and related products to the Aerospace and other vital sectors. The rapid delivery of TKF manufactured tools will assist in the uptake of next generation carbon fibre composite technologies, critical for the production of lightweight fuel-efficient aircraft and equipment to support the UK’s Aircraft and Space Industries. This joint venture will ensure the high-rate production of mould tools, nickel tools and Defence solutions across the UK supply chain, supporting the UK’s position on next-gene

IHS Towers Announces Further Latin America Expansion Through Centennial Towers Acquisition12.4.2021 08:00:00 CEST | Press release

IHS Holding Limited (“IHS Towers”), one of the largest independent owners, operators and developers of shared telecommunications infrastructure in the world by tower count, has acquired Centennial Towers’ Brazilian and Colombian tower operations. This acquisition brings an additional 602 towers in Brazil, and 217 towers in Colombia, strengthening IHS Towers’ position and core expertise in both markets. This latest transaction comes shortly after IHS Towers’ acquisition of Skysites in Brazil and is a testament to the company’s commitment to expanding its business in both Latin American markets. Centennial Towers has extensive expertise in providing mobile network operators with a wide range of infrastructure solutions including Build to Suit towers, Rooftops, Distributed Antenna Systems, Small Cells and Site Colocation & Leasing. These recent acquisitions highlight and demonstrate the continuation of IHS Towers’ growth strategy and demonstrates its 20-year track record of growth and exc

Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting12.4.2021 07:35:00 CEST | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210411005016/en/ Figure 1: Effect of TOTUM•854 supplementation on systolic (SBP) and diastolic (DBP) blood pressure after 3 weeks, in an induced hypertension model (L-NAME model). After 3 weeks, L-NAME induced a 24 mmHg-raise in SBP and a 19 mmHg- raise in DPB (grey bars). Supplementation with TOTUM•854 (blue bars) significantly reduced SBP by 16 mmHg (p<0.01) and DBP by 15 mmHg (p<0.05). (Graphic: Business Wire) VALBIOTIS (FR0013254851 – ALVAL, PEA-SME eligible) (Paris:ALVAL), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the presentation of positive preclinical results of TOTUM•854 in hypertension at the joint meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) held from April 11 to 14, 2021, in virtual format. This research, c

stc pay with UM MENA and InMobi Wins Four Awards at MMA SMARTIES MENA 202012.4.2021 06:00:00 CEST | Press release

stc pay, the leading digital wallet service in Saudi Arabia, won four awards at the MMA SMARTIES MENA 2020, taking home a silver for COVID-19 Campaign of the Year and a total of three bronze awards in the Mobile App, Lead Generation / Direct Response / Conversions and mCommerce categories. The stc pay 'Stay at Home' campaign was the only campaign the MMA SMARTIES MENA recognized in the mCommerce and COVID-19 App categories in 2020. stc pay was awarded in numerous categories for its ‘Stay at Home’ campaign, which was co-facilitated by UM MENA and InMobi, the world’s leading independent marketing cloud. To drive adoption of stc pay’s mobile app beginning in March 2020, especially during Eid and Ramadan, stc pay and UM utilized a three-phased approach with InMobi optimizing for specific in-app events during each phase in addition to the overarching objective of growing stc pay’s user base. Phase one of the campaign ran for most of April and highlighted how stc pay helps app users make tra

Världspremiär från Unicontrol: 3D-maskinstyrning utvecklad efter grävlastarens behov12.4.2021 06:00:00 CEST | Pressmeddelande

Först utvecklade Unicontrol världens första 3D-maskinstyrningssystem med inriktning på mindre grävmaskiner. Nu har danska Unicontrol kommit med en ny innovation och utvecklat ett intuitivt maskinstyrningssystem för grävlastare. Det har skett i nära samarbete med den svenska maskintillverkaren Huddig. Tillsammans har de utvecklat användarvänlig styrning åt maskinföraren, som både ökar användningsmöjligheterna och lönsamheten för grävlastare. Ju mindre maskinerna på en byggarbetsplats står still, desto bättre är det för det ekonomiska resultatet i ett byggprojekt. En grävlastare är en mer allsidig och flexibel maskin än en vanlig grävmaskin. Trots det blir maskintypen ofta bortvald på större byggarbetsplatser, eftersom de har saknat fullständig 3D-maskinstyrning av maskinens olika funktioner. Grävlastarna har inte kunnat samla in alla data och har heller inte varit med i byggbranschens digitaliseringsvåg. Denna utmaning har Unicontrol nu löst tillsammans med Huddig. Parterna har anlitat

EIG Signs $12.4 Billion Infrastructure Deal with Aramco9.4.2021 22:30:00 CEST | Press release

EIG, a leading institutional investor to the global energy sector and one of the world’s leading infrastructure investors, today announced that it has entered into a lease and lease-back agreement with Saudi Arabian Oil Co. ("Aramco"), under which a consortium of investors led by EIG will acquire a 49% equity stake in Aramco Oil Pipelines Company (“Aramco Oil Pipelines”), a newly formed entity with rights to 25-years of tariff payments for oil transported through Aramco’s stabilized crude oil pipeline network. The transaction is valued at approximately $12.4 billion with Aramco holding the remaining 51% stake in the new entity, indicating a total equity value of Aramco Oil Pipelines of approximately $25.3 billion. The pipeline network, which includes all of Aramco’s existing and future stabilized crude pipelines in the Kingdom of Saudi Arabia, connects oilfields to downstream networks. The pipeline network transports 100% of Aramco’s crude oil produced in the Kingdom under its Concessi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom